Pipeline for characterizing alternative mechanisms (PCAM) based on bi-clustering to study colorectal cancer heterogeneity

dc.contributor.authorCao, Sha
dc.contributor.authorChang, Wennan
dc.contributor.authorWan, Changlin
dc.contributor.authorLu, Xiaoyu
dc.contributor.authorDang, Pengtao
dc.contributor.authorZhou, Xinyu
dc.contributor.authorZhu, Haiqi
dc.contributor.authorChen, Jian
dc.contributor.authorLi, Bo
dc.contributor.authorZang, Yong
dc.contributor.authorWang, Yijie
dc.contributor.authorZhang, Chi
dc.contributor.departmentBiostatistics and Health Data Science, School of Medicine
dc.date.accessioned2023-12-15T14:39:54Z
dc.date.available2023-12-15T14:39:54Z
dc.date.issued2023-03-17
dc.description.abstractThe cells of colorectal cancer (CRC) in their microenvironment experience constant stress, leading to dysregulated activity in the tumor niche. As a result, cancer cells acquire alternative pathways in response to the changing microenvironment, posing significant challenges for the design of effective cancer treatment strategies. While computational studies on high-throughput omics data have advanced our understanding of CRC subtypes, characterizing the heterogeneity of this disease remains remarkably complex. Here, we present a novel computational Pipeline for Characterizing Alternative Mechanisms (PCAM) based on biclustering to gain a more detailed understanding of cancer heterogeneity. Our application of PCAM to large-scale CRC transcriptomics datasets suggests that PCAM can generate a wealth of information leading to new biological understanding and predictive markers of alternative mechanisms. Our key findings include: 1) A comprehensive collection of alternative pathways in CRC, associated with biological and clinical factors. 2) Full annotation of detected alternative mechanisms, including their enrichment in known pathways and associations with various clinical outcomes. 3) A mechanistic relationship between known clinical subtypes and outcomes on a consensus map, visualized by the presence of alternative mechanisms. 4) Several potential novel alternative drug resistance mechanisms for Oxaliplatin, 5-Fluorouracil, and FOLFOX, some of which were validated on independent datasets. We believe that gaining a deeper understanding of alternative mechanisms is a critical step towards characterizing the heterogeneity of CRC. The hypotheses generated by PCAM, along with the comprehensive collection of biologically and clinically associated alternative pathways in CRC, could provide valuable insights into the underlying mechanisms driving cancer progression and drug resistance, which could aid in the development of more effective cancer therapies and guide experimental design towards more targeted and personalized treatment strategies. The computational pipeline of PCAM is available in GitHub (https://github.com/changwn/BC-CRC).
dc.eprint.versionFinal published version
dc.identifier.citationCao S, Chang W, Wan C, et al. Pipeline for characterizing alternative mechanisms (PCAM) based on bi-clustering to study colorectal cancer heterogeneity. Comput Struct Biotechnol J. 2023;21:2160-2171. Published 2023 Mar 17. doi:10.1016/j.csbj.2023.03.028
dc.identifier.urihttps://hdl.handle.net/1805/37373
dc.language.isoen_US
dc.publisherElsevier
dc.relation.isversionof10.1016/j.csbj.2023.03.028
dc.relation.journalComputational and Structural Biotechnology Journal
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourcePMC
dc.subjectGene expression data
dc.subjectColorectal cancer
dc.subjectCancer stratification
dc.subjectBi-clustering
dc.subjectAlternative drug resistance mechanism
dc.titlePipeline for characterizing alternative mechanisms (PCAM) based on bi-clustering to study colorectal cancer heterogeneity
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
main.pdf
Size:
5.87 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: